July 14, 2020

July 14, 2020 – Presidio Medical, Inc., a clinical-stage medical device company developing a neuromodulation platform technology with an initial indication to treat chronic pain, today announced it has closed $30 million in financing. The financing round was led by Invus Opportunities, with participation from existing investor, Action Potential Venture Capital. FLG partner Mark Murray assisted in later raising a total of $39M, starting with convertible notes of $20M and ultimately the closing of Series B in two tranches in 2021 (Feb. and June) which included the convertible notes ($20M) plus new money of ($19M).

Company announcement is here.